1 |
Guo L, Yang H, Zhou C, Shi Y, Huang L, Zhang J. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy. Front Immunol 2021;12:773570. [PMID: 34956201 DOI: 10.3389/fimmu.2021.773570] [Reference Citation Analysis]
|
2 |
Wu J, Wei Y, Miao C, Wang S, Wang X, Wang Z, Wang J. Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma. Journal of Oncology 2022;2022:1-29. [DOI: 10.1155/2022/9411692] [Reference Citation Analysis]
|
3 |
Du M, Peng Y, Li Y, Sun W, Zhu H, Wu J, Zong D, Wu L, He X. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. Cell Death Discov 2022;8:53. [PMID: 35136045 DOI: 10.1038/s41420-022-00844-6] [Reference Citation Analysis]
|
4 |
Liu J, Zhou Z, Ma L, Li C, Lin Y, Yu T, Wei JF, Zhu L, Yao G. Effects of RNA methylation N6-methyladenosine regulators on malignant progression and prognosis of melanoma. Cancer Cell Int 2021;21:453. [PMID: 34446007 DOI: 10.1186/s12935-021-02163-9] [Reference Citation Analysis]
|